Evommune, Inc. (EVMN) Investor Relations Documents

Evommune, Inc. (EVMN) investor relations documents from the company's IR site: 2 presentations, 9 press releases; latest deck 2026-08-06. Read in-app with summaries. First-party data.

August Corporate Presentation: Evommune is a mid-stage company with two Phase 2 programs, EVO756 and EVO301, targeting chronic inflammation. It has ~$287M cash through 2028.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-06	Press release	Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
2026-08-06	Presentation	August Corporate Presentation
2026-07-30	Press release	Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
2026-06-29	Press release	Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
2026-05-07	Press release	Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
2026-05-07	Presentation	May 2026 Corporate Presentation
2026-04-06	Press release	Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
2026-03-05	Press release	Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
2026-02-12	Press release	Evommune Announces $125 Million Private Placement
2026-02-10	Press release	Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic De
	Press release	Evommune EVO301 Top-Line Results from Phase 2a Trial in Moderate-to-Severe Atopic Dermatitis

EVMN overview · EVMN earnings · EVMN financials · EVMN KPIs · EVMN ownership · EVMN peers · EVMN filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.